Literature DB >> 17308079

Genetic unmasking of an epigenetically silenced microRNA in human cancer cells.

Amaia Lujambio1, Santiago Ropero, Esteban Ballestar, Mario F Fraga, Celia Cerrato, Fernando Setién, Sara Casado, Ana Suarez-Gauthier, Montserrat Sanchez-Cespedes, Anna Git, Anna Gitt, Inmaculada Spiteri, Partha P Das, Carlos Caldas, Eric Miska, Manel Esteller.   

Abstract

The mechanisms underlying microRNA (miRNA) disruption in human disease are poorly understood. In cancer cells, the transcriptional silencing of tumor suppressor genes by CpG island promoter hypermethylation has emerged as a common hallmark. We wondered if the same epigenetic disruption can "hit" miRNAs in transformed cells. To address this issue, we have used cancer cells genetically deficient for the DNA methyltransferase enzymes in combination with a miRNA expression profiling. We have observed that DNA hypomethylation induces a release of miRNA silencing in cancer cells. One of the main targets is miRNA-124a, which undergoes transcriptional inactivation by CpG island hypermethylation in human tumors from different cell types. Interestingly, we functionally link the epigenetic loss of miRNA-124a with the activation of cyclin D kinase 6, a bona fide oncogenic factor, and the phosphorylation of the retinoblastoma, a tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17308079     DOI: 10.1158/0008-5472.CAN-06-4218

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  346 in total

Review 1.  Identification of driver and passenger DNA methylation in cancer by epigenomic analysis.

Authors:  Satish Kalari; Gerd P Pfeifer
Journal:  Adv Genet       Date:  2010       Impact factor: 1.944

2.  Methylation of miR124a-1, miR124a-2, and miR124a-3 in Hodgkin lymphoma.

Authors:  M Ben Dhiab; S Ziadi; F Ksiaa; T Louhichi; R Ben Gacem; A Ben Zineb; K Amara; M Hachana; Mounir Trimeche
Journal:  Tumour Biol       Date:  2014-11-15

Review 3.  Cancer and neurodegenerative disorders: pathogenic convergence through microRNA regulation.

Authors:  Liqin Du; Alexander Pertsemlidis
Journal:  J Mol Cell Biol       Date:  2011-01-28       Impact factor: 6.216

Review 4.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

5.  Polymorphisms of miRNAs genes are associated with the risk and prognosis of coronary artery disease.

Authors:  Hong Zhi; Lina Wang; Genshan Ma; Xingzhou Ye; Xiaojin Yu; Yi Zhu; Yu Zhang; Jiaju Zhang; Bei Wang
Journal:  Clin Res Cardiol       Date:  2011-12-11       Impact factor: 5.460

Review 6.  Non-coding RNAs in human disease.

Authors:  Manel Esteller
Journal:  Nat Rev Genet       Date:  2011-11-18       Impact factor: 53.242

7.  MicroRNAs, macrocontrol: regulation of miRNA processing.

Authors:  Izabella Slezak-Prochazka; Selvi Durmus; Bart-Jan Kroesen; Anke van den Berg
Journal:  RNA       Date:  2010-04-27       Impact factor: 4.942

Review 8.  Epigenetic modifications and human disease.

Authors:  Anna Portela; Manel Esteller
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

Review 9.  Causes and consequences of microRNA dysregulation.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

Review 10.  MicroRNA as tools and therapeutics in lung cancer.

Authors:  Jennifer F Barger; S Patrick Nana-Sinkam
Journal:  Respir Med       Date:  2015-02-19       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.